Psychedelics for Chronic Pain: What the Research Actually Shows

Chronic pain affects approximately 20 percent of US adults, with about 7 percent reporting high-impact chronic pain that limits daily life or work activities, according to the CDC National Health Interview Survey (2021). Fibromyalgia alone affects roughly 2 to 4 percent of the population, with a strong female predominance, based on the original ACR criteria established by Wolfe and colleagues in 1990. For a meaningful subset of these patients, conventional pharmacology stalls. Gabapentinoids, SNRIs, opioids, and physical therapy each help some people, but a stubborn middle group continues to suffer through full medical management. Psychedelics have entered this gap with a small but expanding body of evidence.

The patient population that responds best is not the one most physicians initially expect. Fibromyalgia, complex regional pain syndrome, chronic widespread pain, irritable bowel, interstitial cystitis, and many functional somatic conditions are now understood as disorders of central pain processing, not peripheral tissue. The pain is real and the mechanism sits in the central nervous system. This is precisely the layer where psychedelics appear to act. For the closely related question of cluster headache, see psilocybin for cluster headaches, which involves a different mechanism in the same neurochemical family.

What follows is a careful look at the chronic pain evidence base, the central sensitization mechanism that psychedelics seem to target, the trauma and alexithymia patterns that consistently appear in this clinical population, and the integration question that defines whether the work actually holds after the session ends.

How Big Is the Chronic Pain Problem Most Medicine Cannot Solve?

An estimated 51.6 million US adults, roughly 20.9 percent of the adult population, reported chronic pain in 2021, with 17.1 million reporting high-impact chronic pain that restricted at least one major life activity, according to the CDC National Health Interview Survey (2021). The figures place chronic pain ahead of diabetes, depression, and high blood pressure as the most common chronic condition in adult medicine. Yet pain receives a fraction of the research funding given to those conditions, and the clinical toolkit for chronic pain remains thin.

The Fibromyalgia Subgroup

Fibromyalgia is the prototypical central pain syndrome and affects 2 to 4 percent of the population, with women diagnosed roughly seven times as often as men, based on the criteria established by Wolfe and colleagues at the American College of Rheumatology in 1990 and subsequently updated. The condition is defined by widespread musculoskeletal pain combined with fatigue, sleep disturbance, cognitive symptoms, and a long list of somatic complaints. Standard care includes duloxetine, milnacipran, pregabalin, and exercise programs, with each helping some patients and none reliably eliminating the pain.

Functional Somatic Syndromes

The broader family of functional somatic conditions, including irritable bowel syndrome, chronic fatigue, temporomandibular disorder, vulvodynia, and chronic pelvic pain, shares the central sensitization mechanism with fibromyalgia. Patients commonly meet criteria for multiple of these conditions simultaneously, which is a clue to the shared underlying neurobiology. The diagnostic siloing by specialty obscures the common pattern. The pain is generated centrally, the body is sensitized to ordinary signals, and conventional medicine is mostly looking in the wrong place.

The Treatment-Resistant Middle

What I keep seeing in founders and senior operators with chronic pain is a similar trajectory. The condition emerges, often after a period of high stress or after a moderate injury that healed but the pain did not. They cycle through specialists, accumulate diagnoses, try the standard medications, and arrive at a stable state of managed but ongoing suffering. The conventional care has done what it can. The next layer is the one most physicians have not been trained to address, which is the central sensitization layer where psychedelics appear to act.

Chronic Pain Is Now Understood as Central, Not Peripheral

Central sensitization, a state in which the central nervous system amplifies pain signals and generates pain in the absence of ongoing tissue injury, is now the dominant framework for understanding fibromyalgia and most functional pain syndromes, according to mechanistic reviews in the broader pain literature. The clinical implication is that the pain is not in the tissues. It is in the way the nervous system processes signals from the tissues. This is not a statement that the pain is imaginary. It is a statement about where the pain is generated.

The Sensitization Cascade

Repeated nociceptive input, sustained inflammation, or psychological stress can produce lasting changes in spinal and supraspinal pain processing. Synapses become more excitable, descending inhibitory pathways weaken, and the cortical representation of the affected body region expands. Functional imaging studies in fibromyalgia show altered activity in the insula, anterior cingulate, and thalamus, regions that integrate pain with emotional and self-referential processing. The pain becomes encoded into the way the brain represents the body.

Why Peripheral Treatments Plateau

If the pain generator is central, peripheral interventions reach a ceiling quickly. NSAIDs do little for fibromyalgia. Opioids work briefly and lose effect, or produce hyperalgesia over time. Tissue-based physical therapy helps mobility and conditioning but does not resolve the central pattern. The conventional pharmacology that does help, duloxetine and pregabalin, works centrally on neurotransmitter systems, which is consistent with the central sensitization model and explains why peripheral drugs disappoint.

The Identity Layer

Across nearly a thousand integration sessions, the pattern that consistently surfaces in long-standing chronic pain is that the pain has been encoded into the patient's self model. The default mode network, which holds the narrative self, has integrated the pain signal into the representation of who the person is. Patients describe this directly, not as metaphor. They say things like "the pain is part of me now" or "I don't know who I would be without it." This is not psychological weakness. It is what years of central sensitization actually do to the self model, and it is the layer psychedelics seem to address.

What Does the Psychedelic Chronic Pain Evidence Actually Show?

Castellanos and colleagues published the most cited review of psychedelics for chronic pain in the Journal of Psychopharmacology in 2020, summarizing case reports, observational data, and mechanistic studies on psilocybin and LSD for headache disorders, phantom limb pain, fibromyalgia, and cancer-related pain (Castellanos et al., Journal of Psychopharmacology, 2020). The review identified a consistent signal across condition categories and called for prospective controlled trials, several of which have since been initiated.

The Castellanos Review

The 2020 paper organized the existing evidence by condition and by mechanism, including the Sewell case series for cluster headache, scattered case reports of psilocybin and LSD use in phantom limb pain, anecdotal fibromyalgia outcomes, and the rationale for central pain processing as the shared target. The authors were careful about the data quality, but the convergence across very different pain conditions pointed to a common mechanism, which they framed as central serotonergic modulation through 5-HT2A receptor activity.

The Michigan Fibromyalgia Pilot

The Frontiers in Pain Research 2025 fibromyalgia pilot at the University of Michigan dosed five women with psilocybin combined with brief psychotherapy, with primary outcome measures including pain severity, pain interference, and quality of life. Pain reduction was clinically meaningful and sustained at the six-week follow-up. The sample is too small for definitive efficacy claims, but the effect size and durability are notable, and the trial design provides a structure that larger studies can build on.

The Whelan and Johnson Headache Trial

Outside the chronic widespread pain literature, Whelan and Johnson (Current Pain and Headache Reports, 2018) reviewed the case for psilocybin and LSD in cluster headache and migraine, summarizing the controlled trial work that the Schindler group at Yale subsequently extended. The cluster headache evidence is the most developed slice of the broader chronic pain literature and serves as a useful proof-of-concept that serotonergic psychedelics can modulate severe pain conditions through central mechanisms.

How Do Psychedelics Actually Modulate Chronic Pain?

The proposed mechanism centers on 5-HT2A receptor activity in cortical and thalamic pain pathways combined with acute suppression of the default mode network, which together loosen the central encoding of pain and the pain-identity fusion that develops in long-standing chronic conditions, per the mechanistic synthesis offered in the Castellanos 2020 review. This is a different therapeutic target than analgesia. The drug is not blocking pain signals. It is changing the way the central nervous system organizes them.

5-HT2A and the Pain Pathway

Classic psychedelics are potent 5-HT2A receptor agonists, and 5-HT2A receptors are densely expressed in cortical regions involved in pain perception, including the anterior cingulate, insula, and somatosensory cortex. Activation of 5-HT2A receptors increases cortical glutamate release, alters thalamocortical signaling, and modulates the descending pain pathways. The acute effects produce the psychedelic experience. The lasting effects on pain appear to involve downstream plasticity changes in the same circuits, with structural and functional adaptations that outlast the drug action by weeks.

Default Mode Network Suppression

The default mode network holds the narrative self and the self-referential processing that integrates ongoing sensation into identity. In chronic pain, the DMN encodes the pain as part of who the person is. Psilocybin and LSD acutely suppress DMN activity and connectivity, which transiently dissolves the rigid pain-identity fusion. The integration window that follows is where the encoding can be reorganized. The body has not changed in the moments after a psychedelic session. The way the self model relates to the body has.

Why This Is Different From Analgesia

Conventional analgesics block pain transmission. Psychedelics do not. A patient on psilocybin who steps on a sharp object still experiences acute pain. The relevant action is not on acute nociception but on the chronic central state that has built up around the pain over months and years. This is consistent with the patient-reported pattern of relief that emerges in the weeks after a session, not during the session, and that often persists when standard analgesics had stopped working. For the related neurobiological context, see somatic psychedelic integration.

What Role Do Trauma and Alexithymia Play in Chronic Pain That Responds to Psychedelics?

Trauma history and alexithymia, meaning difficulty identifying and naming internal emotional states, appear at substantially elevated rates in chronic pain populations and especially in fibromyalgia, with multiple studies placing childhood trauma prevalence near 50 percent in fibromyalgia cohorts compared to roughly 30 percent in general population samples, based on the broader chronic pain literature. The clinical pattern is consistent. The body carries what the verbal system never processed.

The Body as the Holder

Across nearly a thousand integration sessions, the pattern that consistently surfaces in chronic pain clients is that the pain often sits on top of a trauma history that the person has not metabolized, sometimes because the events were preverbal, sometimes because the family system did not allow naming the events, sometimes because the events are continuous enough that no after-state has existed in which to process them. The body becomes the holder of what could not be felt elsewhere. Central sensitization is, in this frame, partly an adaptive response to chronic affective overload that the nervous system processed somatically.

Alexithymia as the Bridge

Alexithymia is a documented correlate of fibromyalgia and many functional somatic conditions, with rates substantially higher than in chronic pain conditions with clear peripheral generators. The connection is mechanistic. If the verbal-affective system cannot reliably read internal emotional states, those states get expressed through the somatic channel that remains available. The pain is real, the mechanism is central, and the function the pain serves in the person's psychological economy can be quite specific. Psychedelics appear to open the alexithymia gap temporarily, allowing the somatic material to become legible to the verbal system.

"For patients with central sensitization on top of unprocessed trauma, the psychedelic session is not aiming at the pain. It is aiming at the material the pain has been holding. The pain gets quieter when the holding job becomes unnecessary."

What This Means for Protocol Design

Chronic pain protocols that ignore the trauma layer tend to produce short-lived relief, with pain returning within weeks as the central sensitization reorganizes around the same unprocessed material. Protocols that integrate trauma-informed psychotherapy with the psychedelic session produce more durable outcomes, which is consistent with what the Michigan fibromyalgia pilot built into its design. The integration practitioner working with this population is doing trauma work, not pain management work, and the distinction matters for who should hold these sessions. For broader integration context, see psychedelic integration therapy.

Integration After Central Sensitization Lifts

For patients whose chronic pain reduces meaningfully after psychedelic-assisted work, the integration period creates an identity reorganization problem that the conventional pain medicine literature has not adequately mapped. The pain has organized daily life for years: pacing, schedule, social commitments, medication routines, the constant low-grade scan of the body. When that organizing principle softens, the absence is not automatically experienced as freedom. Patients describe a strange disorientation, sometimes a grief, sometimes a temporary increase in anxiety.

The Pain Identity Question

Many long-standing chronic pain patients have built relationships, work patterns, and self-concept around the pain. The disability claim, the patient communities, the medical relationships, the family role. None of this is inauthentic. It is what the person actually built. When the central sensitization lifts, the structures that depend on the pain do not immediately reorganize. The integration work involves staying patient with the time it takes for the rest of the system to follow the body. This is identity work, not symptom celebration.

The Medical Reorganization

Patients on duloxetine, pregabalin, opioids, or other pain medications need a plan for whether and how those medications change as the central state responds. This is a physician conversation. The integration work supports the decisional clarity those conversations require, but the actual taper decisions are clinical decisions made with the prescribing physician. Founders and senior operators in particular tend to compress these medical decisions into timeframes the body cannot match, which often produces a rebound that looks like treatment failure but is mostly an over-fast taper.

The Slow Reclamation

What I keep noticing is that the patients who handle the transition best are the ones who do not try to immediately reclaim all the bandwidth the pain had occupied. The freed-up capacity goes into rest, into relationships, into work patterns the central sensitization had been making impossible, but not into a full restructuring of life all at once. The nervous system that has been running on pain-management cortisol for years needs months to recalibrate. The integration window is long, and compressing it tends to be a mistake.

Frequently Asked Questions